Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer
AVROBIO, Inc. (AVRO)
Last avrobio, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.avrobio.com/investor-relations
Company Research
Source: Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic.“Dan is an experienced public-company CFO who will add significant financial expertise to our team,” said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. “With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer.”Dan brings with him a wealth of knowledge in corporate finance, business strategy and operations, in addition to nearly 15 years of healthcare equity investing experience. Prior to joining Tectonic, he served as Chief Business Officer and Chief Financial Officer of Viatris' Eye Care Division following Viatris’ acquisition of Oyster Point Pha
Show less
Read more
Impact Snapshot
Event Time:
AVRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVRO alerts
High impacting AVROBIO, Inc. news events
Weekly update
A roundup of the hottest topics
AVRO
News
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVROPR Newswire
- AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVROBusiness Wire
- Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure [Yahoo! Finance]Yahoo! Finance
- Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart FailureBusiness Wire
AVRO
Sec Filings
- 6/20/24 - Form 8-K
- 6/18/24 - Form 8-K/A
- 6/14/24 - Form 8-K
- AVRO's page on the SEC website